Literature DB >> 33130500

Rhabdoviruses as vectors for vaccines and therapeutics.

Gabrielle Scher1, Matthias J Schnell2.   

Abstract

Appropriate choice of vaccine vector is crucial for effective vaccine development. Rhabdoviral vectors, such as rabies virus and vesicular stomatitis virus, have been used in a variety of vaccine strategies. These viruses have small, easily manipulated genomes that can stably express foreign glycoproteins due to a well-established reverse genetics system for virus recovery. Both viruses have well-described safety profiles and have been demonstrated to be effective vaccine vectors. This review will describe how these Rhabdoviruses can be manipulated for use as vectors, their various applications as vaccines or therapeutics, and the advantages and disadvantages of their use.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Year:  2020        PMID: 33130500      PMCID: PMC8331071          DOI: 10.1016/j.coviro.2020.09.003

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  174 in total

1.  The natural history of vesicular stomatitis.

Authors:  R P HANSON
Journal:  Bacteriol Rev       Date:  1952-09

2.  Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus.

Authors:  Darryl Falzarano; Friederike Feldmann; Allen Grolla; Anders Leung; Hideki Ebihara; James E Strong; Andrea Marzi; Ayato Takada; Shane Jones; Jason Gren; Joan Geisbert; Steven M Jones; Thomas W Geisbert; Heinz Feldmann
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

3.  Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope.

Authors:  K Haglund; J Forman; H G Kräusslich; J K Rose
Journal:  Virology       Date:  2000-03-01       Impact factor: 3.616

4.  Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles.

Authors:  M J Schnell; L Buonocore; E Kretzschmar; E Johnson; J K Rose
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

Review 5.  Preventing rabies with the Verorab vaccine: 1985-2005 Twenty years of clinical experience.

Authors:  Stephen Toovey
Journal:  Travel Med Infect Dis       Date:  2007-09-17       Impact factor: 6.211

6.  Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection.

Authors:  Anasuya Chattopadhyay; Steven Park; Guillaume Delmas; Rema Suresh; Svetlana Senina; David S Perlin; John K Rose
Journal:  Vaccine       Date:  2008-10-01       Impact factor: 3.641

7.  Use of Recombinant Virus Replicon Particles for Vaccination against Mycobacterium ulcerans Disease.

Authors:  Miriam Bolz; Sarah Kerber; Gert Zimmer; Gerd Pluschke
Journal:  PLoS Negl Trop Dis       Date:  2015-08-14

8.  Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever.

Authors:  Sergio E Rodriguez; Robert W Cross; Karla A Fenton; Dennis A Bente; Chad E Mire; Thomas W Geisbert
Journal:  Sci Rep       Date:  2019-05-23       Impact factor: 4.379

9.  Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.

Authors:  Joseph E Blaney; Andrea Marzi; Mallory Willet; Amy B Papaneri; Christoph Wirblich; Friederike Feldmann; Michael Holbrook; Peter Jahrling; Heinz Feldmann; Matthias J Schnell
Journal:  PLoS Pathog       Date:  2013-05-30       Impact factor: 6.823

10.  Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses.

Authors:  Xiangguo Qiu; Lisa Fernando; Judie B Alimonti; P Leno Melito; Friedericke Feldmann; Daryl Dick; Ute Ströher; Heinz Feldmann; Steven M Jones
Journal:  PLoS One       Date:  2009-05-14       Impact factor: 3.240

View more
  5 in total

1.  A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters.

Authors:  Mijia Lu; Yuexiu Zhang; Piyush Dravid; Anzhong Li; Cong Zeng; Mahesh Kc; Sheetal Trivedi; Himanshu Sharma; Supranee Chaiwatpongsakorn; Ashley Zani; Adam Kenney; Chuanxi Cai; Chengjin Ye; Xueya Liang; Jianming Qiu; Luis Martinez-Sobrido; Jacob S Yount; Prosper N Boyaka; Shan-Lu Liu; Mark E Peeples; Amit Kapoor; Jianrong Li
Journal:  J Virol       Date:  2021-08-11       Impact factor: 6.549

2.  Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model.

Authors:  Drishya Kurup; Delphine C Malherbe; Christoph Wirblich; Rachael Lambert; Adam J Ronk; Leila Zabihi Diba; Alexander Bukreyev; Matthias J Schnell
Journal:  PLoS Pathog       Date:  2021-03-25       Impact factor: 6.823

3.  Optimized intramuscular immunization with VSV-vectored spike protein triggers a superior immune response to SARS-CoV-2.

Authors:  Charaf Benarafa; Gert Zimmer; Adriano Taddeo; Inês Berenguer Veiga; Christelle Devisme; Renate Boss; Philippe Plattet; Sebastian Weigang; Georg Kochs; Volker Thiel
Journal:  NPJ Vaccines       Date:  2022-07-25       Impact factor: 9.399

4.  Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune response unaffected by vector immunity.

Authors:  Catherine Yankowski; Christoph Wirblich; Drishya Kurup; Matthias J Schnell
Journal:  NPJ Vaccines       Date:  2022-09-23       Impact factor: 9.399

5.  Towards Development of an Anti-Vampire Bat Vaccine for Rabies Management: Inoculation of Vampire Bat Saliva Induces Immune-Mediated Resistance.

Authors:  Horacio A Delpietro; Roberto G Russo; Charles E Rupprecht; Gabriela L Delpietro
Journal:  Viruses       Date:  2021-03-20       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.